USAN drug names under consideration

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: USAN@ama-assn.org.

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

February 2022

lutetium Lu 177 edotreotide: Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors

taninilast: Treatment of chronic obstructive pulmonary disease and chronic bronchitis

January 2022

anivovetmab: Prevention and treatment of canine parvovirus

detadomulgene voranipalsmid: Treatment of bladder cancer
udifitimod: Autoimmune disorders including atopic dermatitis, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis

December 2021

duvatamig: Treatment of non-small cell lung cancer

firtugratinib: Antineoplastic

zevoprubart: Treatment of autoimmune diseases and prevention of organ transplant rejection

November 2021

None